Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)